✦ LIBER ✦

Postprandial increase in atherogenic remnant-lipoprotein in type 2 diabetes mellitus with fasting normolipidemia

✍ Scribed by N Takayanagi; T Onuma; S Kato; K Abe; T Nomiyama; T Ogihara; T Shimizu; Y Tanaka; Y Usuki; R Kawamori

Book ID: 119434508
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 144 KB
Volume: 151
Category: Article
ISSN: 0021-9150
DOI: 10.1016/s0021-9150(00)80313-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fasting and postprandial lipoproteins in

Fasting and postprandial lipoproteins in type 2 diabetic subjects

✍ Pometta, D.; James, R.W. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Determinants of postprandial triglycerid

Determinants of postprandial triglyceride and remnant-like lipoproteins in type 2 diabetes

✍ K. C. B. Tan; A. W. K. Tso; O. C. K. Ma; R. W. C. Pang; S. Tam; K. S. L. Lam 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

Postprandial Hyperglycemia in Patients w

Postprandial Hyperglycemia in Patients with Type 2 Diabetes Mellitus

✍ Rajasekaran Sudhir, Professor Viswanathan Mohan 📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 182 KB

Does pravastatin increase chylomicron re

Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?

✍ T. W. K. Ng; G. F. Watts; B. G. A. Stuckey; H. L. Ching; D. C. F. Chan; Y. Uchid 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Effects of Simvastatin on Fasting and Po

Effects of Simvastatin on Fasting and Postprandial Triglyceride-Rich Lipoproteins in Patients with Type I Diabetes Mellitus

✍ Marina Noutsou; Angeliki Georgopoulos 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 221 KB

Atherogenic lipoprotein phenotype in Typ

Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate

✍ Michael D. Feher; Muriel Caslake; Julie Foxton; Alison Cox; Christopher J. Packa 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

## Background: To assess the short-term effects of a micronised formulation of fenofibrate on lipids, lipoproteins and their composition, reflecting an atherogenic lipoprotein phenotype (alp), in patients with stable type 2 diabetes. ## Methods: Thirty-two (18 male, 14 female) patients with type